M. de Lima

Pre-MEASURE: FLT3-ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission

S. Zeger, G. Gui, C. Hourigan, 2022, medRxiv.

Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

C. Craddock, V. Brown, C. Hourigan, 2022, Leukemia.

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

M. Robin, G. Garcia-Manero, Z. DeFilipp, 2022, Transplantation and cellular therapy.

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.

S. Zeger, G. Gui, C. Hourigan, 2023, JAMA.

Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome

Omar H. Butt, Gregory F. Wu, B. Ances, 2022, JAMA oncology.

Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care

D. Revicki, G. Garcia-Manero, J. Maciejewski, 2023, Transplantation and cellular therapy.

A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

M. Perales, S. Margevicius, M. Gallogly, 2024, Blood advances.